Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jiangsu Aidea Pharmaceutical Co., Ltd. is a biotechnology firm focused on the development and commercialization of innovative therapeutics, particularly in oncology and autoimmune diseases. The company has established a competitive position in the Chinese market through its proprietary drug formulations and a robust pipeline of candidates in various stages of clinical trials, which are expected to drive future revenue growth.
Jiangsu Aidea generates revenue primarily through the sale of its proprietary therapeutics, which command premium pricing due to their innovative nature and clinical efficacy. The company also engages in collaborative research agreements with larger pharmaceutical firms, providing a steady stream of income while leveraging its R&D capabilities. Its competitive advantages include a strong patent portfolio and a focus on high-demand therapeutic areas, which enhance its pricing power.
Clinical trial results for key drug candidates, particularly in oncology
Regulatory approvals from the National Medical Products Administration (NMPA) in China
Partnership announcements with larger pharmaceutical companies
Market expansion efforts into Southeast Asia
Regulatory changes affecting drug approval processes in China
Technological disruption from new therapeutic modalities such as gene editing
Intensifying competition from domestic and international biotech firms
Potential for generic competition once patents expire
Negative cash flow with free cash flow at -$0.0B, indicating reliance on external financing for operations
High valuation multiples (EV/EBITDA at 131.2x) may pose risks if growth expectations are not met
moderate - The biotechnology sector is somewhat insulated from economic downturns, but funding for R&D can be affected by broader economic conditions.
Higher interest rates can increase the cost of capital for R&D financing, potentially impacting the company's ability to fund clinical trials and development projects.
minimal - The company has a manageable debt-to-equity ratio of 0.76, indicating limited reliance on external credit.
growth - Investors looking for high-growth opportunities in the biotech sector will be attracted to Aidea's innovative pipeline.
high - The stock has exhibited significant volatility, with a 1-year return of -16.2%, reflecting market sensitivity to clinical outcomes.